Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 270

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

Budde, Klemens, Schmouder, Robert L., Brunkhorst, Reinhard, Nashan, Bjorn, Lu[Combining Diaeresis]cker, Peter W., Mayer, Thomas, Choudhury, Somesh, Skerjanec, Andrej, Kraus, Gerolf, Neumayer, Hans H.·2002·Journal of the American Society of Nephrology

Abstract

FTY720 is a novel immunomodulator to be developed for use in organ transplantation. The primary objective of this study was to measure safety, single-dose pharmacokinetics, and pharmacodynamics in stable renal transplant patients-the first human use of FTY720. This study used a randomized, double-blind, placebo-controlled design that explored single oral doses of FTY720 from 0.25 to 3.5 mg in 20 stable renal transplant patients on a cyclosporine-based regimen. Safety assessments and blood samples were taken predose and at multiple time points during a 96-h period postdose. Standard pharmacokinetic parameters were derived from the FTY720 whole blood concentrations, measured by HPLC/MS/MS. FTY720 was well tolerated, with no serious adverse events. Transient, asymptomatic bradycardia occurred after administration in 10 of 24 doses of FTY720. Pharmacokinetics are characterized by a prolonged absorption phase; the terminal elimination phase started 36 h after the administration, with elimination half-life (t(1/2)) ranging from 89 to 157 h independent of dose. Maximum plasma concentration and AUC were proportional to dose with low intersubject variability, the apparent volume of distribution (V(d)/F) ranged from 1116 to 1737 L. FTY pharmacodynamics were characterized by a reversible transient lymphopenia within 6 h, the nadir being 42% of baseline. The lymphocyte count returned to baseline within 72 h in all dosing cohorts except the highest. Single oral doses of FTY720 ranging from 0.25 to 3.5 mg were well tolerated and caused a reversible selective lymphopenia. Transient, but asymptomatic bradycardia was the most common adverse event. The long t(1/2) suggests less frequent dosing intervals. The size of V(d)/F is in excess of blood volume, consistent with widespread tissue distribution

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.v1341073

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 270

Metadata

Authors
Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H.
Venue
Journal of the American Society of Nephrology
Published
2002-04
Volume
13
Issue
4
Pages
1073-1083
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2165704853
Cited by
270
References
13
FWCI
16.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients. https://app.cochat.ai/papers/10.1681/asn.v1341073
The paper
Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H. (2002). First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v1341073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.